|
Valoración DCF de Foghorn Therapeutics Inc. (FHTX)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Foghorn Therapeutics Inc. (FHTX) Bundle
¡Simplifique la valoración de Foghorn Therapeutics Inc. (FHTX) con esta calculadora DCF personalizable! Con Real Foghorn Therapeutics Inc. (FHTX) financieras y entradas de pronóstico ajustable, puede probar escenarios y descubrir Foghorn Therapeutics Inc. (FHTX) Valor razonable en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .4 | 1.3 | 19.2 | 34.2 | 57.9 | 98.0 | 166.1 | 281.3 | 476.6 |
| Revenue Growth, % | 0 | 0 | 206.74 | 1357.77 | 77.63 | 69.41 | 69.41 | 69.41 | 69.41 | 69.41 |
| EBITDA | -48.8 | -66.5 | -96.2 | -113.8 | -104.5 | -34.7 | -58.8 | -99.6 | -168.8 | -285.9 |
| EBITDA, % | 100 | -15463.72 | -7292.42 | -591.93 | -305.83 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | 1.8 | 5.5 | 7.5 | 7.9 | 3.5 | 40.6 | 68.8 | 116.6 | 197.6 | 334.7 |
| Depreciation, % | 100 | 1285.58 | 569.75 | 41.09 | 10.1 | 70.24 | 70.24 | 70.24 | 70.24 | 70.24 |
| EBIT | -50.6 | -72.0 | -103.7 | -121.7 | -107.9 | -34.7 | -58.8 | -99.6 | -168.8 | -285.9 |
| EBIT, % | 100 | -16749.3 | -7862.17 | -633.02 | -315.93 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 15.0 | 185.8 | 154.3 | 345.8 | 234.1 | 57.9 | 98.0 | 166.1 | 281.3 | 476.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 300.0 | .0 | .0 | 23.1 | 39.2 | 66.4 | 112.5 | 190.6 |
| Account Receivables, % | 100 | 0 | 22744.5 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Inventories | .0 | .0 | .0 | .0 | .0 | 11.6 | 19.6 | 33.2 | 56.3 | 95.3 |
| Inventories, % | 100 | 0 | 0 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
| Accounts Payable | 3.4 | 3.7 | 3.8 | 5.4 | 6.3 | 40.1 | 67.9 | 115.1 | 194.9 | 330.2 |
| Accounts Payable, % | 100 | 855.81 | 289.54 | 28.16 | 18.33 | 69.3 | 69.3 | 69.3 | 69.3 | 69.3 |
| Capital Expenditure | -1.0 | -16.2 | -3.3 | -1.2 | -1.2 | -24.3 | -41.1 | -69.7 | -118.1 | -200.0 |
| Capital Expenditure, % | 100 | -3763.49 | -251.18 | -6.29 | -3.58 | -41.98 | -41.98 | -41.98 | -41.98 | -41.98 |
| Tax Rate, % | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 | -4.49 |
| EBITAT | -51.1 | -73.0 | -105.7 | -121.7 | -112.7 | -34.7 | -58.8 | -99.6 | -168.8 | -285.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -46.9 | -83.5 | -401.3 | 186.6 | -109.7 | -19.2 | -27.4 | -46.4 | -78.6 | -133.1 |
| WACC, % | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 | 16.6 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -170.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -136 | |||||||||
| Terminal Value | -930 | |||||||||
| Present Terminal Value | -431 | |||||||||
| Enterprise Value | -601 | |||||||||
| Net Debt | -35 | |||||||||
| Equity Value | -566 | |||||||||
| Diluted Shares Outstanding, MM | 42 | |||||||||
| Equity Value Per Share | -13.49 |
What You Will Get
- Pre-Filled Financial Model: Foghorn Therapeutics Inc.'s (FHTX) actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers specific to FHTX.
- Instant Calculations: Automatic updates ensure you see results as you make changes to FHTX's financials.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation of FHTX.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts of FHTX.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as drug development timelines, market penetration rates, and R&D expenditures.
- Instant DCF Valuation: Quickly computes intrinsic value, net present value (NPV), and other financial metrics.
- High-Precision Accuracy: Leverages Foghorn Therapeutics' actual financial data for credible valuation insights.
- Streamlined Scenario Testing: Easily evaluate various hypotheses and analyze different outcomes.
- Efficiency Booster: Avoid the complexities of creating detailed valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Foghorn Therapeutics Inc.'s pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Foghorn Therapeutics Inc. (FHTX)?
- Precision: Utilizes accurate Foghorn Therapeutics financial data for reliable calculations.
- Customizability: Allows users to adjust and experiment with various inputs seamlessly.
- Efficiency: Eliminates the need to create a financial model from the ground up.
- Expert-Level: Crafted with the expertise and detail expected at the CFO level.
- Intuitive: Designed for ease of use, catering to individuals with varying levels of financial expertise.
Who Should Use This Product?
- Investors: Evaluate Foghorn Therapeutics Inc.'s (FHTX) valuation before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and assess future projections for FHTX.
- Biotech Entrepreneurs: Understand the valuation models applied to companies like Foghorn Therapeutics Inc. (FHTX).
- Consultants: Create comprehensive valuation reports for clients in the biotech sector.
- Students and Educators: Utilize current market data to explore and teach valuation strategies in biotechnology.
What the Template Contains
- Pre-Filled Data: Includes Foghorn Therapeutics Inc.'s (FHTX) historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Foghorn Therapeutics Inc.'s (FHTX) profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.